Zosano Pharma Corporation (NASDAQ:ZSAN) is scheduled to be releasing its earnings data after the market closes on Thursday, August 10th. Analysts expect Zosano Pharma Corporation to post earnings of ($0.19) per share for the quarter.

Zosano Pharma Corporation (NASDAQ:ZSAN) last announced its quarterly earnings results on Tuesday, May 9th. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.04. On average, analysts expect Zosano Pharma Corporation to post $-0.97 EPS for the current fiscal year and $-0.99 EPS for the next fiscal year.

Shares of Zosano Pharma Corporation (ZSAN) opened at 1.04 on Wednesday. Zosano Pharma Corporation has a one year low of $0.45 and a one year high of $3.54. The company’s market capitalization is $40.77 million. The company’s 50 day moving average is $1.33 and its 200 day moving average is $1.58.

In other Zosano Pharma Corporation news, CEO John Peter Walker purchased 73,716 shares of Zosano Pharma Corporation stock in a transaction on Thursday, May 25th. The shares were acquired at an average cost of $1.36 per share, for a total transaction of $100,253.76. Following the completion of the transaction, the chief executive officer now directly owns 169,344 shares of the company’s stock, valued at $230,307.84. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, CFO Georgia Erbez bought 68,000 shares of the business’s stock in a transaction dated Thursday, May 25th. The stock was purchased at an average price of $1.32 per share, for a total transaction of $89,760.00. Following the acquisition, the chief financial officer now directly owns 115,750 shares of the company’s stock, valued at approximately $152,790. The disclosure for this purchase can be found here. 2.95% of the stock is owned by company insiders.

Separately, ValuEngine cut shares of Zosano Pharma Corporation from a “sell” rating to a “strong sell” rating in a research report on Monday, July 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. Zosano Pharma Corporation presently has a consensus rating of “Hold” and an average price target of $2.58.

COPYRIGHT VIOLATION WARNING: “Zosano Pharma Corporation (NASDAQ:ZSAN) Scheduled to Post Quarterly Earnings on Thursday” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and republished in violation of United States and international copyright law. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/08/09/zosano-pharma-corporation-nasdaqzsan-scheduled-to-post-quarterly-earnings-on-thursday.html.

Zosano Pharma Corporation Company Profile

Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The Company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers consistent drug delivery and improved ease of use and room-temperature stability.

Earnings History for Zosano Pharma Corporation (NASDAQ:ZSAN)

Receive News & Stock Ratings for Zosano Pharma Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma Corporation and related stocks with our FREE daily email newsletter.